IQIRVO® data expands scientific evidence in fatigue, showing clinically meaningful improvements in patients with moderate-to-severe fatigue at ...

Backed by the phase 2b/3 EPICS-III trial, saroglitazar demonstrated a significant 56.7% biochemical response rate compared with 9.8% for placebo, while showing favorable safety data.

RTY-406 demonstrates significant improvements in disease relevant endpoints in a mouse model of primary sclerosing cholangitis (PSC) and proof of ...

Acute cholangitis, also known as ascending cholangitis, is a serious disorder of the biliary system, which can be life-threatening, if left untreated. The most frequent reason of obstruction of the ...

Cholangitis is bile duct inflammation that can block bile flow and cause it to back up into the liver. This can cause liver damage without treatment. Symptoms vary by type and may be mild at first, ...

The US FDA has granted priority review to Saroglitazar, Zydus Lifesciences' drug for treating Primary Biliary Cholangitis ...

This page lists all known medications that could potentially lead to 'Cholangitis' as a side effect. It's important to note that mild side effects are quite common with medications. The medication(s) ...

A single day of antibiotic treatment is noninferior to a standard 4- to 7-day course for acute cholangitis following adequate endoscopic biliary drainage, with fewer antibiotic-related adverse events, ...

The cholangitis infection is often caused by bacteria, a gallstone or any another blockage. Primary biliary cholangitis is a chronic condition where inflammation of the bile duct system keeps bile ...

Primary biliary cholangitis (PBC) and Primary sclerosing cholangtiis (PSC) are both progressive bile duct-related liver diseases, with similar symptoms and effects. Both diseases cause the gradual ...